Pathophysiological Mechanisms and Clinical Management of Weight Loss Plateaus in GLP-1 Receptor Agonist Therapy: A Comprehensive Analysis of Metabolic Adaptation and Advanced Dosing Strategies

The pharmacological landscape of obesity management has undergone a profound transformation with the development and clinical integration of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These agents, including semaglutide and the dual GLP-1/GIP agonist tirzepatide, have demonstrated the capacity to induce weight loss previously achievable only through bariatric surgery.1 Despite these advancements, a nearly universal clinical observation is the weight loss plateau—a point at which, despite continued medication adherence and lifestyle modification, the patient’s body weight remains stationary.1 This phenomenon is not an indicator of medication failure but rather a manifestation of a sophisticated biological defense mechanism designed to maintain energy homeostasis.1 The cessation of weight loss is the result of a multifaceted interplay between metabolic adaptation, hormonal counter-regulation, and pharmacological receptor dynamics.1

The Biological Foundations of the Weight Loss Plateau

The cessation of weight loss during GLP-1 RA therapy typically manifests between six and twelve months after the initiation of treatment, frequently coinciding with the attainment of 70% to 80% of the total expected weight reduction.4 To address this stagnation, clinicians must recognize that the human body functions as a homeostatic system that perceives significant weight loss as a threat to survival.2

Metabolic Adaptation and Adaptive Thermogenesis

At the core of the weight loss plateau is metabolic adaptation, a natural biological response where the body defends its energy stores by reducing its energy expenditure.1 As a patient loses weight, their basal metabolic rate (BMR)—the energy required to maintain basic physiological functions at rest—naturally decreases because a smaller body mass requires less energy to sustain itself.7 However, the decline in energy expenditure often exceeds what would be predicted based solely on the reduction in body mass, a process termed adaptive thermogenesis.2

When caloric intake is restricted, the body increases its metabolic efficiency to conserve energy.2 This response is mediated by the hypothalamus, which integrates peripheral signals to adjust the BMR.8 Research indicates that during active weight loss, the BMR can decrease by 10% to 25%, effectively narrowing or closing the caloric deficit that was initially responsible for weight loss.4 This reduction in “calories out” eventually matches the “calories in” facilitated by the medication’s appetite suppression, leading to a state of energy equilibrium where weight loss stalls.1

Hormonal Counter-Regulation and the Return of Hunger

The biological defense against weight loss is further supported by profound changes in the circulating levels of appetite-regulating hormones.2 Weight loss triggers a compensatory surge in ghrelin, the primary hunger-stimulating hormone produced in the stomach.1 Simultaneously, there is a reduction in satiety-promoting hormones such as leptin, peptide YY (PYY), and cholecystokinin (CCK).2

Leptin, produced by adipose tissue, serves as a signal to the brain regarding the state of energy stores; as fat mass decreases, leptin levels drop, signaling the hypothalamus to increase hunger and reduce energy expenditure.2 This hormonal shift creates a “tug-of-war” between the pharmacological effects of the GLP-1 RA and the body’s endogenous signals.8 Many patients report the return of “food noise”—intrusive thoughts about eating—during this period, even while maintaining their medication dose.1

Receptor Desensitization and Gastric Emptying Rebound

Pharmacological tolerance also plays a role in the emergence of plateaus. The GLP-1 receptor itself may become less responsive to a constant level of agonist stimulation over time, a process known as receptor desensitization or downregulation.1 This is a common feature of receptor-based therapies where chronic exposure to a ligand leads to a reduction in receptor density or signaling efficiency.4

Additionally, the gastrointestinal effects of GLP-1 RAs often undergo adaptation. One of the primary mechanisms for early weight loss is delayed gastric emptying, which induces a prolonged sense of fullness.1 Over several months of treatment, the stomach’s emptying rate may gradually return toward its baseline, a phenomenon called gastric emptying rebound.1 While the central effects of the medication on the brain’s appetite centers may persist, the loss of this mechanical satiety component contributes significantly to the slowing of weight loss.1

Clinical Strategies to Overcome Weight Loss Plateaus

When a weight loss plateau is reached, clinicians must evaluate several physiological and pharmacological factors to determine the most appropriate intervention. Plateaus are often a signal that the body has reached a new “set point,” and breaking through this resistance requires a multi-pronged approach.6

Pharmacological Escalation and Switching Protocols

The most direct clinical response to a weight loss stall is the titration of the medication to its maximum therapeutic dose.1 Many patients experience plateaus because they are on a sub-therapeutic dose or have not yet completed the full titration schedule, which is designed to minimize gastrointestinal side effects.3 Clinical trials, such as the STEP and SURMOUNT programs, have consistently demonstrated that higher doses of semaglutide and tirzepatide result in greater total body weight reduction.3

For patients who have reached the maximum dose of a single-hormone agonist like semaglutide but have plateaued, switching to a dual-incretin therapy like tirzepatide may be effective.2 Tirzepatide acts on both GLP-1 and GIP receptors, providing a synergistic effect that further suppresses appetite and improves metabolic markers beyond what GLP-1 alone can achieve.2 GIP signaling is believed to enhance the body’s sensitivity to GLP-1 while also potentially modifying adipocyte metabolism to favor fat oxidation.2

Adjunctive Pharmacotherapy and Combination Treatments

In some cases, the addition of a second anti-obesity medication is necessary to overcome significant metabolic resistance.11 The combination of a GLP-1 RA with phentermine, a sympathomimetic amine that stimulates norepinephrine release to suppress appetite, has been used clinically to “jumpstart” weight loss during a plateau.26 Similarly, the combination of phentermine and topiramate (Qsymia) can be used as an adjunct.27 Topiramate, an anti-epileptic medication, is thought to promote satiety and reduce cravings through GABAergic modulation and glutamate antagonism.28

The “Muscle Floor” and Resistance Training

A critical and often overlooked factor in weight loss plateaus is the loss of lean muscle mass.11 Rapid weight loss on GLP-1 RAs can result in a significant portion of the loss coming from muscle rather than fat—estimates suggest up to 40% in some populations.12 Muscle tissue is more metabolically active than adipose tissue; thus, the loss of muscle further depresses the BMR, making continued weight loss nearly impossible.7

The body may reach a “muscle floor,” where it resists further weight loss to prevent the depletion of essential lean mass.32 To counter this, patients must prioritize resistance training two to three times per week and ensure an adequate intake of high-quality protein (typically 0.8 to 1.2 grams per kilogram of body weight).11 Preserving or building muscle mass helps maintain a higher BMR and can “re-prime” the metabolism to resume fat loss.13

Advanced Dosing Schedules and Off-Label Dosing Intervals

As weight loss stalls, some clinical protocols and patient-led initiatives have explored the modification of the standard seven-day dosing interval.34 The most common adjustment is shortening the interval to an injection every six days.34

Pharmacokinetic Rationale for Six-Day Dosing

The pharmacokinetics of the most common weekly GLP-1 RAs are governed by their relatively long half-lives: semaglutide has a half-life of approximately seven days (168 hours), and tirzepatide has a half-life of approximately five days (120 hours).20 These long durations of action are achieved through molecular modifications that enhance stability and reduce renal clearance, allowing the medication to reach a “steady state” in the body after four to five weeks of regular dosing.21

Steady state represents a dynamic equilibrium where the amount of drug administered equals the amount eliminated between doses.38 In a standard seven-day cycle, the plasma concentration of the medication reaches its peak () within one to three days post-injection and then declines to its trough level () by day seven.20 Shortening the interval to six days effectively increases the accumulation factor of the medication.38

The accumulation factor () is determined by the formula:

where is the elimination rate constant () and is the dosing interval.38 By reducing from seven days to six days, the average concentration () and the trough concentration () are raised.39 Clinically, this is intended to prevent the “wear-off” effect often reported by patients toward the end of their weekly cycle, where appetite suppression wanes as the drug concentration approaches the trough.1

The Side Effects of Increased Dosing Frequency

Increasing the frequency of GLP-1 RA injections to every six days is an off-label practice that significantly alters the drug’s safety profile.15 The side effects of these medications are profoundly dose-dependent, and shortening the interval results in higher sustained concentrations and higher peaks than those validated in clinical trials.3

Intensified Gastrointestinal Distress

The most frequent adverse effects—nausea, vomiting, diarrhea, and constipation—are largely mediated by the slowing of gastric motility and the activation of satiety centers in the brain.9 A six-day dosing schedule can overwhelm the body’s ability to adapt to these effects.17 Patients who were stable on a seven-day schedule may experience a resurgence of severe nausea or vomiting as the steady-state concentration rises.41 In extreme cases, this can lead to clinical gastroparesis, where gastric emptying is slowed to a degree that compromises nutritional intake and hydration.44

Risk of Dehydration and Renal Injury

Chronic vomiting and diarrhea associated with high-dose GLP-1 therapy can lead to rapid volume depletion.20 Dehydration is a primary cause of acute kidney injury (AKI) in this patient population.41 Shortening the dosing interval increases the likelihood of persistent gastrointestinal distress, thereby escalating the risk of renal complications.20 Clinicians often monitor renal function and electrolytes closely in patients who deviate from standard dosing schedules.5

Cardiovascular and Endocrine Considerations

GLP-1 RAs are known to cause a mild increase in resting heart rate, typically 2 to 4 beats per minute.41 Escalating the dose frequency may lead to more pronounced tachycardia or palpitations, which can be distressing for patients with underlying cardiac conditions.26 Additionally, while GLP-1 RAs have a low risk of hypoglycemia when used alone, the risk increases significantly if the dose is concentrated or if the patient is also taking insulin or sulfonylureas.20

The Role of Lifestyle Factors in Plateau Management

While pharmacological adjustments are often the focus of plateau management, lifestyle factors such as sleep, stress, and behavioral consistency are equally critical in determining long-term outcomes.6

Sleep, Stress, and Cortisol

Chronic sleep deprivation and high levels of stress are potent inhibitors of weight loss, even on GLP-1 medications.6 Poor sleep disrupts the balance of hunger hormones, increasing ghrelin and decreasing leptin, which can bypass the appetite-suppressing effects of the medication.6 Stress triggers the release of cortisol, which promotes the storage of visceral fat and increases cravings for calorie-dense foods.6 Managing these factors is often a prerequisite for breaking a plateau that appears resistant to medication adjustments.11

Behavioral Drift and “Hidden” Calories

Over time, patients may experience behavioral drift, where the dietary habits established at the beginning of treatment begin to loosen.7 Small increases in portion sizes, the reintroduction of liquid calories, or frequent snacking can add up to enough calories to offset the metabolic slowdown, resulting in a weight stall.11 Brief periods of food logging or meeting with a registered dietitian can help patients identify these “hidden” calories and realign their intake with their new, lower energy requirements.11

Pharmacokinetic Modeling of Alternative Regimens: A Comparative View

The decision to modify a dosing regimen must be grounded in an understanding of how frequency changes affect the steady-state concentration and the therapeutic window.17

Comparison of Weekly vs. Bi-Weekly vs. Monthly Efficacy

Recent mathematical modeling of semaglutide and tirzepatide has investigated the relationship between dosing frequency and weight loss retention.39 These models reveal a non-linear relationship between the amount of drug administered and the biological response.39

For example, reducing the dosing frequency from once-weekly to once every two weeks (effectively halving the total drug amount over time) does not result in a 50% reduction in efficacy.39 Instead, patients retain approximately 72% to 75% of their weight loss.39 This suggests that the body’s response to higher or more frequent doses eventually reaches a point of diminishing returns, where additional drug increases the risk of side effects significantly more than it increases weight loss.15

The “Steady State” Equilibrium

Reaching steady state is crucial because it ensures consistent appetite regulation throughout the week.21 When the dosing interval is shortened to six days, the body reaches a new, higher steady state.38 While this may suppress late-cycle hunger, it also increases the risk of receptor saturation, where all available GLP-1 receptors are occupied, and further increases in drug concentration provide no additional therapeutic benefit—only additional toxicity.15

Comprehensive Management Framework for the Plateaued Patient

Managing a weight loss plateau in GLP-1 therapy requires a systematic approach that addresses the biological, pharmacological, and behavioral drivers of stagnation.

Phase 1: Re-Evaluation and Diagnostics

The initial step is to confirm the existence of a true plateau (weight stability for >4 weeks) and rule out secondary medical causes.4 Clinicians may perform metabolic testing, such as measuring the Resting Metabolic Rate (RMR) or using DEXA scans to assess body composition changes.13 Laboratory evaluations for thyroid function (TSH), cortisol levels, and sex hormones (testosterone, estrogen) can identify hormonal imbalances that may be contributing to the stall.10

Phase 2: Nutritional and Exercise Optimization

Before adjusting medication, the foundational pillars of weight management must be optimized.11 This includes:

1. Protein Prioritization: Ensuring the patient consumes 1.2g/kg of protein to preserve the BMR.18
2. Resistance Training: Implementing a progressive strength program to counteract adaptive thermogenesis.13
3. Fiber and Hydration: Managing constipation and ensuring satiety through whole-food volume and adequate water intake.12

Phase 3: Pharmacological Intervention

If lifestyle optimization is insufficient, pharmacological adjustments are introduced:

1. Titration to Max Dose: Completing the standard escalation to 2.4 mg (semaglutide) or 15 mg (tirzepatide).3
2. Switching Agents: Transitioning from a GLP-1 RA to a dual GLP-1/GIP RA to leverage synergistic pathways.2
3. Combination Therapy: Adding phentermine or topiramate for dual-mechanism appetite control.26
4. Dosing Frequency Modification: As a final, off-label step, some clinicians may consider shortening the interval to six days, while providing intensive counseling on the risks of GI distress and dehydration.38

The Future of Obesity Management and the Plateau

As the clinical understanding of GLP-1 and other incretin-based therapies evolves, the goal of treatment is shifting from rapid weight loss to sustainable metabolic health.9 Emerging therapies, such as the triple agonist retatrutide (targeting GLP-1, GIP, and glucagon receptors), aim to bypass current plateaus by further increasing metabolic rate and fat oxidation.2

However, for the majority of patients, the plateau is an inevitable part of the journey—a signal that the body has successfully adjusted to a lower energy state.1 Recognizing this adaptation as a physiological milestone rather than a clinical failure allows for a more rational and empathetic approach to long-term obesity management.1 The “chronic disease” model of obesity implies that management will be lifelong, involving the titration and maintenance of pharmacological tools alongside the preservation of the body’s metabolic machinery.9

In summary, weight loss plateaus are driven by the body’s homeostatic defense mechanisms, primarily metabolic adaptation, hormonal shifts, and pharmacological receptor desensitization.1 Strategies to overcome these stalls include maximizing medication doses, switching to dual-agonist therapies, prioritizing resistance training for muscle preservation, and addressing environmental inhibitors such as poor sleep and high stress.2 While advanced dosing strategies like a six-day injection interval may raise steady-state drug levels to suppress lingering hunger, they must be balanced against a significant risk of intensified gastrointestinal side effects and potential renal complications.17

Works cited

1. Why GLP-1 Plateaus Happen and How Telehealth Programs …, accessed May 10, 2026, https://www.how-dept.com/mayiknow/detail/?p=Why-GLP-1-Plateaus-Happen-and-How-Telehealth-Programs-Address-Them-AvGMFw9N72X9k
2. Semaglutide Plateauing? Overcoming Stalled Weight Loss by Switching – Drip Gym, accessed May 10, 2026, https://dripgym.com/blogs/news/semaglutide-weight-loss-plateau-switching-options
3. Evaluating Dose Titration in Semaglutide and Tirzepatide for Weight Loss: A Retrospective Academic Call Center Study – MDPI, accessed May 10, 2026, https://www.mdpi.com/2673-4168/5/4/90
4. GLP-1 Plateau: Why You Stopped Losing Weight and What to Do – Doctronic, accessed May 10, 2026, https://www.doctronic.ai/blog/glp-1-plateau/
5. How to Break a Weight Loss Plateau with GLP-1 Therapy – Harmony Aesthetics Medical Spa, accessed May 10, 2026, https://harmonyaestheticsspa.com/how-to-break-a-weight-loss-plateau/
6. What To Do If You Plateau On A GLP-1 Medication – Spruce Aesthetics + Infusion Bar, accessed May 10, 2026, https://sprucespa.com/what-to-do-if-you-plateau-on-a-glp-1-medication/
7. Why You’re Hitting a Weight-Loss Plateau on Semaglutide (and What to Do About It) – Greenwich Medical Spa, accessed May 10, 2026, https://www.greenwichmedicalspa.com/blog/why-youre-hitting-a-weight-loss-plateau-on-semaglutide-and-what-to-do-about-it/
8. Metabolic Adaptation | Rethink Obesity®, accessed May 10, 2026, https://www.rethinkobesity.com/obesity-disease/metabolic-adaptation.html
9. GLP-1 Balanced: How to Maintain Results Long Term, accessed May 10, 2026, https://revistas.ucatolicaluisamigo.edu.co/plugins/generic/pdfJsViewer/pdf.js/web/viewer.html?file=%2Findex.php%2Findex%2Flogin%2FsignOut%3Fsource%3D%2Egifx7%2Ecom&io0=ctrnbcxbg1jh
10. How Do I Break a Weight Loss Plateau? Understanding Metabolic Set Points – Blue Sky MD, accessed May 10, 2026, https://blueskymd.com/how-do-i-break-a-weight-loss-plateau-understanding-metabolic-set-points/
11. Frustrated by GLP-1? Why Weight Stalls & Medically Approved Next Steps | Ubie Doctor’s Note, accessed May 10, 2026, https://ubiehealth.com/doctors-note/glp1-frustrated-weight-stalls-medics-next-steps-4723e2
12. Weight Loss Stalling While on GLP-1s – Torrance Memorial, accessed May 10, 2026, https://www.torrancememorial.org/healthy-living/blog/weight-loss-stalling-while-on-glp-1s/
13. Tips for Overcoming a Weight-Loss Plateau – Banner Health, accessed May 10, 2026, https://www.bannerhealth.com/healthcareblog/advise-me/how-to-get-over-your-weight-loss-plateau
14. How to Overcome Weight Loss Plateaus With GLP-1 – Sota Wellness, accessed May 10, 2026, https://sotawellness.com/blog/strategies-and-tips-for-overcoming-weight-loss-plateaus-with-glp-1-medications/
15. GLP-1 Microdosing for Weight Loss: Pros and Cons | Paloma Health, accessed May 10, 2026, https://www.palomahealth.com/learn/glp-1-microdosing-weight-loss-pros-cons
16. How to Safely Restart GLP-1 Medications After a Break | Mochi Health, accessed May 10, 2026, https://joinmochi.com/blogs/how-to-restart-after-taking-a-break-from-glp-1s
17. GLP-1 Microdosing Chart: How GLP Activate Supports Your Journey, accessed May 10, 2026, https://cuaderno.pucmm.edu.do/plugins/generic/pdfJsViewer/pdf.js/web/viewer.html?file=%2Findex.php%2Findex%2Flogin%2FsignOut%3Fsource%3D%2Egifx7%2Ecom&io0=t7of2cxp6koo
18. Stalled on Tirzepatide? Why Your Body Plateaus & Approved Medical Steps | Ubie Doctor’s Note, accessed May 10, 2026, https://ubiehealth.com/doctors-note/tirzepatide-stalled-plateau-body-approved-steps-4223e2
19. GLP-1 Dose Adjustment for Weight Loss: When to Adjust – Healthline, accessed May 10, 2026, https://www.healthline.com/health/drugs/glp-1-dose-adjustment-for-weight-loss
20. Semaglutide – StatPearls – NCBI Bookshelf, accessed May 10, 2026, https://www.ncbi.nlm.nih.gov/books/NBK603723/
21. Half-Life of Mounjaro: Dosing, Duration and Clinical Implications …, accessed May 10, 2026, https://www.boltpharmacy.co.uk/guide/half-life-of-mounjaro
22. A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist – PMC, accessed May 10, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12052016/
23. UPDATES to the GLP1-RA Dose Comparisons Chart, accessed May 10, 2026, https://www.wafp.org/assets/files/pdfs/GLP%20equivalent%20Doses%20UPDATED%20chart.pdf
24. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor | Request PDF – ResearchGate, accessed May 10, 2026, https://www.researchgate.net/publication/381442121_Tirzepatide_modulates_the_regulation_of_adipocyte_nutrient_metabolism_through_long-acting_activation_of_the_GIP_receptor
25. (PDF) Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism – ResearchGate, accessed May 10, 2026, https://www.researchgate.net/publication/345315409_Chronic_glucose-dependent_insulinotropic_polypeptide_receptor_GIPR_agonism_desensitizes_adipocyte_GIPR_activity_mimicking_functional_GIPR_antagonism
26. Why Combine Phentermine and GLP-1? Understanding This Powerful Weight Loss Strategy, accessed May 10, 2026, https://www.valleymedicalweightloss.com/blog/why-combine-phentermine-and-glp-1/
27. Phentermine and topiramate (oral route) – Side effects & dosage – Mayo Clinic, accessed May 10, 2026, https://www.mayoclinic.org/drugs-supplements/phentermine-and-topiramate-oral-route/description/drg-20075700
28. Topiramate and phentermine for weight loss: Is it effective? – Healthline, accessed May 10, 2026, https://www.healthline.com/health/drugs/topiramate-and-phentermine
29. How to Take Qsymia for Weight Loss: Dos And Don’ts – GoodRx, accessed May 10, 2026, https://www.goodrx.com/qsymia/how-to-take
30. Diabetes Drugs by Class, accessed May 10, 2026, https://www.wwhealth.org/wp-content/uploads/2016/05/I.-Meds-reduced-2021_reduced.pdf
31. US20240390464A1 – Treatment of Adults With Overweight or Obesity With or Without Weight-Related Comorbidities – Google Patents, accessed May 10, 2026, https://patents.google.com/patent/US20240390464A1/en
32. Stopping and restarting certain GLP-1s to lose weight may make the drug less effective, accessed May 10, 2026, https://www.pennmedicine.org/news/stopping-and-restarting-glp1s-may-make-it-less-effective
33. Maintenance Dosing with Tirzepatide and Semaglutide: What the data tells us., accessed May 10, 2026, https://levesqueplasticsurgery.com/blog/maintenance-dosing-with-tirzepatide-and-semaglutide-whats-the-data-tells-us
34. acting GLP-1 receptor agonist, exendin-4–Fc fusion – RSC Publishing, accessed May 10, 2026, https://pubs.rsc.org/en/content/articlepdf/2017/ra/c7ra10822b
35. In vitro and in vivo characterization of a novel long-acting GLP-1 receptor agonist, exendin-4–Fc fusion protein – RSC Publishing, accessed May 10, 2026, https://pubs.rsc.org/en/content/articlehtml/2017/ra/c7ra10822b
36. US11707610B2 – Ingestible device for delivery of therapeutic agent to the gastrointestinal tract – Google Patents, accessed May 10, 2026, https://patents.google.com/patent/US11707610B2/en
37. INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT – European Patent Office – EP 4309722 A2 – Googleapis.com, accessed May 10, 2026, https://patentimages.storage.googleapis.com/48/f3/bf/5e64a5d5a8a90d/EP4309722A2.pdf
38. Does GLP-1 Build Up in Your System? Understanding Steady State – Bolt Pharmacy, accessed May 10, 2026, https://www.boltpharmacy.co.uk/guide/does-glp-1-build-up-in-your-system
39. Alternative dosing regimens of GLP‐1 receptor agonists may reduce …, accessed May 10, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11885104/
40. Microdosing GLP-1s: Does It Work? Risks and Benefits – GoodRx, accessed May 10, 2026, https://www.goodrx.com/conditions/weight-loss/microdosing-glp-1
41. Glucagon-Like Peptide-1 Receptor Agonists – StatPearls – NCBI Bookshelf, accessed May 10, 2026, https://www.ncbi.nlm.nih.gov/books/NBK551568/
42. GLP-1 Agonists – Cleveland Clinic, accessed May 10, 2026, https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
43. Missed GLP-1 Dose: What happens, what to do, and how to prevent it – Healthline, accessed May 10, 2026, https://www.healthline.com/health/drugs/missed-glp-1-dose
44. Oral Semaglutide for Weight Loss: Key Facts About the Wegovy Pill – GoodRx, accessed May 10, 2026, https://www.goodrx.com/conditions/weight-loss/oral-semaglutide-weight-loss
45. Switching between weight-loss medications – The Pharmaceutical Journal, accessed May 10, 2026, https://pharmaceutical-journal.com/article/ld/switching-between-weight-loss-medications
46. Clinical Pharmacokinetics of Semaglutide: A Systematic Review – PMC, accessed May 10, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11215664/
47. Use of a GLP-1R Agonist to Treat Opioid Use Disorder NCT number: NCT04199728 Docume – ClinicalTrials.gov, accessed May 10, 2026, https://cdn.clinicaltrials.gov/large-docs/28/NCT04199728/Prot_SAP_000.pdf